Amgen’s Repatha proves effective in major cardiovascular outcomes study
Check out details of Amgen Cholesterol Injection phase 3 trial results which demonstrated that Repatha cholesterol injection with statin therapy reduce heart attack, stroke chances.
Amgen Inc. has achieved a significant milestone with its cholesterol-lowering injection, Repatha (evolocumab), demonstrating a 20% reduction in heart attack and stroke risks among patients with heart diseases, according to results from a comprehensive phase 3 cardiovascular outcomes study. Groundbreaking Results in Cardiovascular Prevention The study, named FOURIER, involved 27,564 patients who were at risk […]